StemBioSys

About StemBioSys

StemBioSys Inc. operates as a privately held biomedical company based in San Antonio, Texas, specializing in technologies for the isolation, growth, and delivery of stem cells and other difficult-to-culture cells for research applications. The company was founded in 2010 after a chance meeting in Shanghai between Dr. Xiao-Dong Chen, a tenured professor at UT Health San Antonio, and Dr. Steven Davis, a local dermatologist. Dr. Chen developed the core technology out of frustration with conventional cell culture methods that caused mesenchymal stem cells (MSCs) to lose their essential properties. To solve this, he created a substrate that mimics the natural microenvironment where stem cells reside, leading to the formation of StemBioSys and the licensing of the technology from the university.

The company's business model centers on the sale of its proprietary cell culture products and harvested cells to a diverse client base that includes biopharmaceutical companies, academic laboratories, and private research institutions like the National Institutes of Health. These products are sold for research-use only, facilitating work in drug discovery and basic research. Revenue is generated through the sale of these specialized products, with prices for its matrix plates ranging from approximately $35 to $175. The company experienced a 20% revenue growth between 2021 and 2022 and has raised significant capital through multiple funding rounds, including a Series A of $8 million in 2015 and an oversubscribed Series C of $6.6 million in 2021.

StemBioSys's flagship product line is branded under the CELLvo™ name. The core offering is the CELLvo™ Matrix, a cell-derived extracellular matrix (ECM) that replicates the biochemical and structural cues of the native cellular niche. This environment allows cells to be cultured while retaining their natural phenotypes, proliferative capabilities, and potency for more passages than traditional plastic cultureware. The product portfolio includes various specialized matrices like CELLvo™ Matrix Plus for cardiomyocyte maturation, CELLvo™ NeuroMatrix for neural cells, and CELLvo™ ChondroMatrix for cartilage cells. Beyond matrices, the company also provides early-passage primary cells that have been isolated and expanded exclusively on the CELLvo™ Matrix, such as MSCs, human chondrocytes, and endothelial progenitor cells, ensuring they maintain a more natural state. A key benefit of this technology is its potential to provide a more biologically relevant alternative to animal testing for preclinical safety and toxicity screening.